Massachusetts Eye and Ear Infirmary

masseyeandear.org

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

100

Active

29

Phase 3

6

Total enrollment

11,587

Pipeline matrix

Showing 16 of 16 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Triamcinolone Acetonide 40mg/mL1
Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin1
Prednisolone 1%1
Atropine 1%1
Netarsudil Ophthalmic2
Lactobacillus plantarum 299v1
N-acetyl cysteine (NAC) 10% solution1
N-acetyl cysteine (NAC) 20% solution1
Visine Dry Eye Relief eye drops1
Aspirin1
Doxycycline Injection [Doxy]1
Atorvastatin 80mg1
Dexamethasone2
Topotecan1
Adalimumab1
Laryngeal sensory block with topical bupivacaine1

Next readouts

  • 2026-04-29
  • 2026-07-25
  • 2026-08
  • 2026-09
  • 2026-09-01
  • 2027-03-01
  • 2027-04-01
  • 2027-06-01
  • 2027-08-31
  • 2027-12-01

Top conditions

  • Glaucoma7
  • Spasmodic Dysphonia4
  • Vestibular Schwannoma4
  • Vestibular Disorder4
  • Laryngeal Dystonia3
  • Tremor3
  • Homonymous Hemianopia3
  • Rhegmatogenous Retinal Detachment3

Frequently asked questions about Massachusetts Eye and Ear Infirmary

How many clinical trials does Massachusetts Eye and Ear Infirmary have on ClinicalTrials.gov?
Massachusetts Eye and Ear Infirmary is listed as the lead sponsor on 100 clinical trials in ClinicalTrials.gov, 29 of which are currently active (recruiting, enrolling, or ongoing).
How many of Massachusetts Eye and Ear Infirmary's trials are in Phase 3?
6 of Massachusetts Eye and Ear Infirmary's trials are in Phase 3, spread across 16 active drug programs.
What therapeutic areas does Massachusetts Eye and Ear Infirmary focus on?
Massachusetts Eye and Ear Infirmary's most-studied conditions on ClinicalTrials.gov are Glaucoma, Spasmodic Dysphonia, Vestibular Schwannoma, Vestibular Disorder, Laryngeal Dystonia.
When are Massachusetts Eye and Ear Infirmary's next clinical trial readouts?
Massachusetts Eye and Ear Infirmary has 10 upcoming primary-completion readouts tracked here; the soonest is “Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy”, expected around 2026-04-29.